BIM2

Age-related Macular Degeneration // Barbara Blodi // Clinical Trials // Genetics // Ongoing // Dec 01 2020

Biomarker Identification for anti-VEGF Resistance in Exudative AMD

  • Investigator Initiated
  • Principal Investigator: Barbara Blodi, MD
  • Study Coordinator: Bonnie Verges

Study objective:

To identify whether genetic variation or polymorphism in genes that impact angiogenesis can be identified as biomarkers for responsiveness to anti-VEGF therapy in patients with neovascular age-related macular degeneration.

Study design:

One study visit involving collection of a blood sample for genetic/DNA analysis.

Inclusion criteria:

  • Male or female patients ˃ 50 years of age with diagnosis of age-related macular degeneration in both eyes
  • Patients with exudative age-related macular degeneration in at least one eye undergoing regular treatment with one or more anti-VEGF agents in the past year. Regular treatment would be 4 or more injections per year.

Exclusion criteria:

  • Presence of atrophy or fibrosis under the center of the macula

Contact Bonnie Verges with questions, 608-265-5292